BIOMARKERS is a distinguished journal published by Taylor & Francis Ltd, focusing on the critical intersection of biochemistry, clinical biochemistry, and health-related toxicology. With a robust history of publication since 1996 and ongoing contributions through to 2024, the journal serves as a vital platform for researchers, professionals, and students keen on exploring innovative biomarker research that spans various domains within the life sciences. The journal is currently ranked in the Q3 quartile in key areas such as Biochemistry and Health, demonstrating its reputation in the scientific community. Although it operates under a subscription model, BIOMARKERS remains an essential resource for advancing knowledge on biomarkers in health and disease, reflecting the latest advancements and methodologies within the rapidly evolving landscape of biomedical research. Researchers looking to publish in this influential journal can expect a rigorous peer-review process aimed at ensuring the dissemination of high-quality scientific inquiry.

Translational Research, published by Elsevier Science Inc, stands at the forefront of the rapidly evolving fields of biochemistry, medicine, physiology, and public health. With an impressive 2023 Q1 ranking in these categories, this journal has established itself as a critical platform for disseminating innovative research that bridges the gap between laboratory findings and clinical application. The journal, which has been converging knowledge since 2006, is committed to advancing scientific understanding and improving health outcomes by publishing high-quality articles that reflect rigorous peer review and impactful findings. With its impressive Scopus rankings, including a rank of #5 in Biochemistry and #7 in Physiology, it is an essential resource for researchers, practitioners, and students dedicated to the translation of scientific breakthroughs into real-world health solutions. Transitioning to an open-access model, the journal enhances accessibility and engagement, inviting a global audience to participate in the discourse shaping the future of healthcare and disease management.

CURRENT OPINION IN IMMUNOLOGY is a prestigious journal dedicated to the dynamic field of immunology, published by CURRENT BIOLOGY LTD in the United Kingdom. With an ISSN of 0952-7915 and an E-ISSN of 1879-0372, this journal has been a cornerstone of scholarly communication since its inception in 1988 and continues to disseminate cutting-edge research and reviews aimed at advancing our understanding of immune responses. Holding a remarkable Q1 ranking in both Immunology and Allergy categories for 2023, it ranks impressively within the top percentiles in its field, securing 27th233 in Immunology and Allergy and 31st out of 236 in Immunology and Microbiology. Emphasizing high-impact research, the journal provides researchers, professionals, and students with valuable insights into emerging trends and critical developments. As a vital resource in immunological research, it serves as a platform for disseminating innovative findings, fostering collaboration, and enhancing scholarly exchange in a rapidly evolving scientific landscape.

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.

Annual Review of Pathology: Mechanisms of Disease is a premier scholarly journal published by ANNUAL REVIEWS that systematically reviews significant advancements in the field of pathology and the mechanisms underpinning various diseases. With an ISSN of 1553-4006 and an E-ISSN of 1553-4014, the journal has established its importance within the academic community, evidenced by its prestigious Q1 rankings in several categories including medicine, pathology, forensic medicine, and plant science for 2023. Notably, it ranks #1 out of 208 in the pathology and forensic medicine category, placing it in the 99th percentile according to Scopus metrics. Although not an open-access journal, it offers crucial insights to researchers, professionals, and students alike by providing a comprehensive understanding of pathophysiological concepts and emerging trends. The journal continues to be an essential resource for those dedicated to advancing research and practical applications in disease mechanisms.

The Biomedical Journal, published by ELSEVIER, serves as a premier platform for disseminating groundbreaking research in the field of medicine, specifically within the Q1 category of Medicine (Miscellaneous). With the ISSN 2319-4170 and E-ISSN 2320-2890, this Open Access journal has been committed to advancing biomedical science since its inception in 2002. With an impressive Scopus rank of #31 out of 636 in General Medicine and a notable placement in the 95th percentile, the journal provides valuable insights and rigorous studies that contribute significantly to the medical community. Based in the Netherlands at RADARWEG 29, 1043 NX AMSTERDAM, the journal is highly regarded for its timely and diverse range of articles, fostering collaboration and innovation amidst researchers, professionals, and students alike. The ongoing engagement in the journal's converged years from 2012 to 2024 underscores its commitment to keeping pace with the evolving landscape of biomedical research, making it an essential resource for those seeking to stay at the forefront of medical advancements.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, published by Taylor & Francis AS, serves as a pivotal platform for facilitating advanced research and discourse in the fields of Genetics, Molecular Biology, Molecular Medicine, and Pathology. With an impressive Impact Factor and a distinguished status as Q2 in multiple categories, along with a prestigious Q1 ranking in Pathology and Forensic Medicine (2023), this journal continues to attract contributions from leading experts and budding researchers alike. The journal aims to address critical developments in molecular diagnostics, providing insightful reviews that propel the understanding and application of diagnostic techniques in various medical contexts. Accessible to a diverse audience in the academic community, the journal emphasizes the importance of molecular diagnostics in both clinical and laboratory settings, promoting innovative methodologies and comprehensive evaluations of emerging technologies. With ongoing convergence of scientific discovery advancing rapidly from 2001 through 2024, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS remains essential for those committed to furthering the fields of molecular diagnostics and healthcare advancements globally.

CYTOKINE is a prestigious peer-reviewed journal published by Academic Press Ltd - Elsevier Science Ltd, dedicated to advancing the field of immunology, biochemistry, and related biomedical sciences since its inception in 1989. With an ISSN of 1043-4666 and an E-ISSN of 1096-0023, this journal serves as a vital resource for researchers and professionals alike, offering cutting-edge research findings that delve into the roles and mechanisms of cytokines in health and disease. Recognized for its impactful contributions, CYTOKINE currently ranks in the Q2 quartile across several categories, including Biochemistry, Hematology, and Immunology, indicating its significant influence in these fields. Despite not offering open access, the journal maintains a high-quality standard, as evidenced by its robust Scopus rankings, including a notable 80th percentile in Medicine and Hematology. Researchers and students are encouraged to explore the latest findings and methodologies via CYTOKINE, as it continues to shape the future landscape of cytokine research and application.

EXPERIMENTAL AND MOLECULAR MEDICINE, published by SpringerNature, is a premier open-access journal that has been at the forefront of biomedical research since its establishment in 1996. With a focus on innovative studies in biochemistry, molecular biology, and clinical biochemistry, the journal has consistently maintained a distinguished position within the top quartile (Q1) across multiple categories, underscoring its significant impact in these fields. The journal offers researchers and practitioners a platform for high-quality, peer-reviewed articles that advance our understanding of molecular mechanisms underlying health and disease. As a crucial resource for scholars seeking to explore cutting-edge research and practical advancements, its inclusion in relevant databases such as Scopus reflects an exceptional ranking with notable percentiles—placing it among the best in biomedical sciences. With a commitment to open access, EXPERIMENTAL AND MOLECULAR MEDICINE ensures that findings are readily available to the global academic community, facilitating collaboration and innovation in molecular medicine.